A Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Vaccinations of Ad26.RSV.preF One Year Apart in Adults Aged 60 Years and Older in Stable Health

NCT02926430 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

BIOLOGICAL: Ad26.RSV.preF 5*10^10 vp
BIOLOGICAL: Ad26.RSV.preF 1*10^11 vp
DRUG: Placebo

Sponsor

Janssen Vaccines & Prevention B.V.